Farnesyltransferase Inhibitors in Cancer Therapy -

Farnesyltransferase Inhibitors in Cancer Therapy

Buch | Hardcover
280 Seiten
2000
Humana Press Inc. (Verlag)
978-0-89603-629-1 (ISBN)
171,19 inkl. MwSt
The recent explosion of knowledge gained from genes capable of causing cancer have opened up new avenues for designing anticancer drugs. This volume describes the efforts of several groups in the design and evaluation of these inhibitors.
Cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farensyltransferase inhibitors (FTIs); geranylgeranyltransferase inhibitors (GGTIs) are also discussed as potential anticancer drugs. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors.

1 Signal Transduction Pathways: A Goldmine for Therapeutic Targets.- 2 The Biochemistry of Farnesyltransferase and Geranylgeranyltransferase I.- 3 Structures of Protein Farnesyltransferase.- 4 Peptidomimetic-Based Inhibitors of Farnesyltransferase.- 5 Antitumor Efficacy of a Farnesyltransferase Inhibitor in Transgenic Mice.- 6 Development of Farnesyltransferase Inhibitors as Potential Antitumor Agents.- 7 Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation.- 8 Histidylbenzylglycinamides: A Novel Class of Farnesyl DiphosphateCompetitive Peptidic Farnesyltransferase Inhibitors.- 9 From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase.- 10 Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors.- 11 Effects of Farnesyltransferase Inhibitors on Cytoskeleton, Cell Transformation, and Tumorigenesis: The FTI-Rho Hypothesis.- 12 Prenyltransferase Inhibitors as Radiosensitizers.- 13 Farnesyltransferase and Geranylgeranyltransferase I Inhibitors as Novel Agents for Cancer and Cardiovascular Diseases.- 14 Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases.- 15 Early Clinical Experience with Farnesyl Protein Transferase Inhibitors: From the Bench to the Bedside.- 16 Phase I Trial of Oral R115777 in Patients with Refractory Solid Tumors: Preliminary Results.- 17 Farnesyltransferase and Geranylgeranyltransferase Inhibitors: The Saga Continues.

Erscheint lt. Verlag 22.10.2000
Reihe/Serie Cancer Drug Discovery and Development
Zusatzinfo XII, 280 p.
Verlagsort Totowa, NJ
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Naturwissenschaften Chemie Technische Chemie
ISBN-10 0-89603-629-4 / 0896036294
ISBN-13 978-0-89603-629-1 / 9780896036291
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00

von Stein Husebø; Gebhard Mathis; Eva Katharina Masel

Buch | Softcover (2023)
Springer (Verlag)
49,99